>Go!
NEWS SEARCH

10.27.2017 | Investors

Allergan Board of Directors Announces Fourth Quarter 2017 Cash Dividend and Increases Quarterly Cash Dividend for 2018

-- Underscores Allergan's Continued Strong Cash Flow, Commitment to Enhancing Shareholder Value --

DUBLIN, Oct. 27, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the record and payment dates for a cash dividend of $0.70 per ordinary share for the fourth quarter of 2017. The dividend will be paid on December 15, 2017 to shareholders of record at the close of business on November 17, 2017.

Allergan plc logo

The Company also announced that its Board of Directors has approved an increase to its quarterly cash dividend for 2018 to $0.72 per ordinary share.

"Following authorization of our new $2 billion share repurchase program in September, today's board approval to increase Allergan quarterly cash dividend for 2018 underscores our confidence in our long-term business outlook and strong cash flows.  We expect to continue to increase our dividend on an annual basis," said Brent Saunders, Chairman and CEO of Allergan.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Payment of the ordinary share dividend is subject to applicable law.  Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS: 

Allergan:


Investors:


Daphne Karydas


(862) 261-8006




Media:


Mark Marmur


(862) 261-7558

View original content with multimedia:http://www.prnewswire.com/news-releases/allergan-board-of-directors-announces-fourth-quarter-2017-cash-dividend-and-increases-quarterly-cash-dividend-for-2018-300544550.html

SOURCE Allergan plc

Media Contacts
Mark Marmur
Global Corporate Media Relations
+1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
+1 (201) 427-8762
Janet Kettels
International Product Media Relations
+44 773 850 6476

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488